Ke‐Neng Chen

6.3k total citations · 1 hit paper
77 papers, 1.7k citations indexed

About

Ke‐Neng Chen is a scholar working on Pulmonary and Respiratory Medicine, Surgery and Oncology. According to data from OpenAlex, Ke‐Neng Chen has authored 77 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 49 papers in Pulmonary and Respiratory Medicine, 31 papers in Surgery and 31 papers in Oncology. Recurrent topics in Ke‐Neng Chen's work include Lung Cancer Diagnosis and Treatment (27 papers), Lung Cancer Treatments and Mutations (24 papers) and Esophageal Cancer Research and Treatment (16 papers). Ke‐Neng Chen is often cited by papers focused on Lung Cancer Diagnosis and Treatment (27 papers), Lung Cancer Treatments and Mutations (24 papers) and Esophageal Cancer Research and Treatment (16 papers). Ke‐Neng Chen collaborates with scholars based in China, Ethiopia and United States. Ke‐Neng Chen's co-authors include Jonathan Spicer, Xiaozheng Kang, Moïshe Liberman, Wanpu Yan, Heather A. Wakelee, Margarita Majem, Se‐Hoon Lee, Masahiro Tsuboi, Silvia Novello and E. Eigendorff and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Ke‐Neng Chen

75 papers receiving 1.7k citations

Hit Papers

Perioperative Pembrolizumab for Early-Stage Non–Small-Cel... 2023 2026 2024 2025 2023 100 200 300 400
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Perioperative Pembrolizumab for Early-Stage Non–Small-Cell Lung Cancer
    2023 460 citations Heather A. Wakelee, Moïshe Liberman et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ke‐Neng Chen China 21 1.0k 882 386 334 272 77 1.7k
Myung‐Ju Ahn South Korea 20 990 1.0× 792 0.9× 175 0.5× 139 0.4× 250 0.9× 75 1.5k
Elide Matano Italy 14 863 0.8× 907 1.0× 260 0.7× 161 0.5× 228 0.8× 48 1.5k
Joachim Pfannschmidt Germany 23 1.5k 1.4× 1.0k 1.2× 686 1.8× 199 0.6× 190 0.7× 69 2.2k
Paul E. Van Schil Belgium 19 2.0k 1.9× 1.2k 1.4× 436 1.1× 378 1.1× 327 1.2× 68 2.7k
Catherine Kennedy Australia 23 1.1k 1.0× 785 0.9× 227 0.6× 370 1.1× 484 1.8× 38 2.0k
Giuseppe Fornarini Italy 22 562 0.5× 597 0.7× 305 0.8× 166 0.5× 245 0.9× 125 1.3k
Kimi Kondo United States 14 838 0.8× 649 0.7× 260 0.7× 222 0.7× 444 1.6× 28 1.4k
Miso Kim South Korea 25 710 0.7× 1.2k 1.4× 248 0.6× 208 0.6× 292 1.1× 87 1.7k
A. Crellin United Kingdom 20 857 0.8× 1.0k 1.1× 809 2.1× 354 1.1× 126 0.5× 47 1.8k
Jared Weiss United States 24 1.1k 1.0× 1.1k 1.2× 630 1.6× 349 1.0× 430 1.6× 104 2.2k

Countries citing papers authored by Ke‐Neng Chen

Since Specialization
Citations

This map shows the geographic impact of Ke‐Neng Chen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ke‐Neng Chen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ke‐Neng Chen more than expected).

Fields of papers citing papers by Ke‐Neng Chen

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ke‐Neng Chen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ke‐Neng Chen. The network helps show where Ke‐Neng Chen may publish in the future.

Co-authorship network of co-authors of Ke‐Neng Chen

This figure shows the co-authorship network connecting the top 25 collaborators of Ke‐Neng Chen. A scholar is included among the top collaborators of Ke‐Neng Chen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ke‐Neng Chen. Ke‐Neng Chen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Garassino, Marina Chiara, Heather A. Wakelee, Jonathan Spicer, et al.. (2024). Health-related quality of life (HRQoL) outcomes from the randomized, double-blind phase 3 KEYNOTE-671 study of perioperative pembrolizumab for early-stage non-small-cell lung cancer (NSCLC).. Journal of Clinical Oncology. 42(16_suppl). 8012–8012. 2 indexed citations
2.
Zhao, Ze-Rui, Wanpu Yan, Jingbo Zhang, et al.. (2024). Adjuvant immunotherapy does not improve survival in non–small cell lung cancer with major/complete pathologic response after induction immunotherapy. Journal of Thoracic and Cardiovascular Surgery. 169(6). 1576–1584.e3. 2 indexed citations
3.
Fang, Wentao, Chun Chen, Ke‐Neng Chen, et al.. (2024). China Anti-Cancer Association Guidelines for the diagnosis, treatment, and follow-up of thymic epithelial tumors (2023). Mediastinum. 8. 27–27. 1 indexed citations
4.
Wakelee, Heather A., Moïshe Liberman, Terufumi Kato, et al.. (2023). KEYNOTE-671: Randomized, double-blind, phase 3 study of pembrolizumab or placebo plus platinum-based chemotherapy followed by resection and pembrolizumab or placebo for early stage NSCLC.. Journal of Clinical Oncology. 41(17_suppl). LBA100–LBA100. 11 indexed citations
5.
Wang, Changli, Ke‐Neng Chen, Qixun Chen, et al.. (2023). Abstract CT081: Neoadjuvant nivolumab (NIVO) + chemotherapy (chemo) vs chemo in Chinese patients (pts) with resectable NSCLC in CheckMate 816. Cancer Research. 83(8_Supplement). CT081–CT081. 1 indexed citations
6.
Yan, Wanpu, Wen‐Zhao Zhong, Yan‐Hui Liu, et al.. (2022). Adebrelimab (SHR-1316) in Combination With Chemotherapy as Perioperative Treatment in Patients With Resectable Stage II to III NSCLCs: An Open-Label, Multicenter, Phase 1b Trial. Journal of Thoracic Oncology. 18(2). 194–203. 20 indexed citations
7.
Dai, Liang, Ziming Wang, Zhiqiang Xue, et al.. (2020). Results of surgical treatment for primary malignant melanoma of the esophagus: A multicenter retrospective study. Journal of Thoracic and Cardiovascular Surgery. 161(1). 294–302. 13 indexed citations
8.
Qiu, Bin, Xiaozheng Kang, Ke‐Neng Chen, et al.. (2019). Clinical outcomes following an initial experience with a novel powered vascular stapler in video-assisted thoracoscopic lobectomies: results of a Chinese multi-center study. Journal of Thoracic Disease. 11(5). 1973–1979. 4 indexed citations
9.
Fang, Wentao, Zhitao Gu, & Ke‐Neng Chen. (2018). Minimally Invasive Surgery in Thymic Malignances. SHILAP Revista de lepidopterología. 1 indexed citations
10.
11.
Qi, Liping, Ke‐Neng Chen, Xiaohong Joe Zhou, et al.. (2018). Conventional MRI to detect the differences between mass-like tuberculosis and lung cancer. Journal of Thoracic Disease. 10(10). 5673–5684. 17 indexed citations
12.
Chen, Ke‐Neng, et al.. (2017). Discrimination of Malignant versus Benign Mediastinal Lymph Nodes Using Diffusion MRI with an IVIM Model. European Radiology. 28(3). 1301–1309. 21 indexed citations
13.
Kang, Xiaozheng, Zhen Huang, Anhui Shi, et al.. (2016). [Deficiencies in the Diagnosis and Treatment of Pulmonary Metastatic Osteosarcoma: A Chinese Multidisciplinary Survey].. SHILAP Revista de lepidopterología. 19(3). 153–60. 1 indexed citations
14.
Shen, Yi, Peng Zhang, Chun Chen, et al.. (2016). [Management of Thymic Tumors - Consensus Based on the Chinese Alliance for Research in Thymomas Multi-institutional Retrospective Studies].. SHILAP Revista de lepidopterología. 19(7). 414–7. 3 indexed citations
15.
Chen, Ke‐Neng, Hao Fu, Zhitao Gu, et al.. (2015). P01: Long-term survival after surgical treatment of thymic carcinoma.. Journal of Thoracic Disease. 7(3). 1. 1 indexed citations
16.
17.
Fan, Mengying, Liang Dai, Xiaozheng Kang, et al.. (2015). The expression of TTF-1 and Napsin A in early-stage lung adenocarcinoma correlates with the results of surgical treatment. Tumor Biology. 36(10). 8085–8092. 17 indexed citations
18.
19.
Zang, Mengqing, Ke‐Neng Chen, & Peirong Yu. (2010). Reconstruction of Large Tracheal Defects in a Canine Model: Lessons Learned. Journal of Reconstructive Microsurgery. 26(6). 391–399. 7 indexed citations
20.
Chen, Ke‐Neng, et al.. (1998). The diagnosis and treatment for recurrent dysphagia of esophageal carcinoma after radical radiotherapy. Chinese Journal of Cancer Research. 10(1). 71–73. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Myung‐Ju Ahn Breakdown of academic impact, for papers by Elide Matano Breakdown of academic impact, for papers by Joachim Pfannschmidt Breakdown of academic impact, for papers by Paul E. Van Schil Breakdown of academic impact, for papers by Catherine Kennedy Breakdown of academic impact, for papers by Giuseppe Fornarini Breakdown of academic impact, for papers by Kimi Kondo Breakdown of academic impact, for papers by Miso Kim Breakdown of academic impact, for papers by A. Crellin Breakdown of academic impact, for papers by Jared Weiss
Rankless by CCL
2026